NasdaqCM - Delayed Quote USD

KALA BIO, Inc. (KALA)

3.4200
-0.0100
(-0.29%)
At close: May 9 at 4:00:00 PM EDT
3.3999
-0.02
(-0.59%)
After hours: May 9 at 6:58:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
3,892
11,240
Cost of Revenue
--
--
0
2,560
4,097
Gross Profit
--
--
0
1,332
7,143
Operating Expense
34,235
34,235
34,328
82,688
116,576
Operating Income
-34,235
-34,235
-34,328
-81,356
-109,433
Net Non Operating Interest Income Expense
-3,727
-3,727
-3,103
-6,602
-8,276
Other Income Expense
-549
-549
-4,768
43,136
-24,896
Pretax Income
-38,511
-38,511
-42,199
-44,822
-142,605
Net Income Common Stockholders
-38,511
-38,511
-42,199
-44,822
-142,605
Diluted NI Available to Com Stockholders
-38,511
-38,511
-42,199
-44,822
-142,605
Basic EPS
-11.67
-10.15
-17.35
-29.48
-108.32
Diluted EPS
-11.67
-10.15
-17.35
-29.48
-108.32
Basic Average Shares
3,299.6430
3,796.0470
2,432.0080
1,520.6110
1,316.4950
Diluted Average Shares
3,299.6430
3,796.0470
2,432.0080
1,520.6110
1,316.4950
Total Operating Income as Reported
-40,983
-40,983
-39,663
-81,706
-130,245
Total Expenses
34,235
34,235
34,328
85,248
120,673
Net Income from Continuing & Discontinued Operation
-38,511
-38,511
-42,199
-44,822
-142,605
Normalized Income
-37,962
-37,962
-41,689
-88,884
-116,398
Interest Income
2,056
2,056
2,711
664
104
Interest Expense
5,783
5,783
5,814
7,266
8,380
Net Interest Income
-3,727
-3,727
-3,103
-6,602
-8,276
EBIT
-32,728
-32,728
-36,385
-37,556
-134,225
EBITDA
-32,469
-32,469
-36,082
-37,019
-133,250
Reconciled Cost of Revenue
--
--
0
2,560
4,097
Reconciled Depreciation
259
259
303
537
975
Net Income from Continuing Operation Net Minority Interest
-38,511
-38,511
-42,199
-44,822
-142,605
Total Unusual Items Excluding Goodwill
-549
-549
-510
44,062
-26,207
Total Unusual Items
-549
-549
-510
44,062
-26,207
Normalized EBITDA
-31,920
-31,920
-35,572
-81,081
-107,043
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/20/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MGNX MacroGenics, Inc.
1.4300
-7.14%
 
MRSN Mersana Therapeutics, Inc.
0.3189
-4.81%
 
GLYC GlycoMimetics, Inc.
0.2402
-0.95%
 
ASMB Assembly Biosciences, Inc.
12.24
+4.97%
 
CDTX Cidara Therapeutics, Inc.
18.63
-2.72%
 
KYMR Kymera Therapeutics, Inc.
30.07
-2.27%
 
CTMX CytomX Therapeutics, Inc.
0.9284
-14.83%
 
XNCR Xencor, Inc.
8.33
-5.23%
 
TENX Tenax Therapeutics, Inc.
5.57
-2.02%
 
IMCR Immunocore Holdings plc
28.40
-4.67%